BCRP is overexpressed in many malignancies and contributes to poor chemotherapeutic response in acute myelogenous leukemia (AML), chronic myeloid leukemia (CML), pancreatic ductal adenocarcinomas, non-small lung cancer cells (NSCLC), and other solid tumors (10). This evidence concerns the gene ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive.